08:13 AM EDT, 10/03/2024 (MT Newswires) -- Avidity Biosciences ( RNA ) said Thursday the US Food and Drug Administration has lifted the partial clinical hold on investigational therapy delpacibart etedesiran.

Delpacibart etedesiran, which is intended as a treatment for myotonic dystrophy type 1, is being tested in the ongoing phase 3 HARBOR trial, the company said.

Myotonic dystrophy type 1 is a progressive neuromuscular disease that affects skeletal and cardiac muscle, resulting in symptoms like muscle weakness, respiratory issues, and cardiac abnormalities, according to the company statement.

Avidity Biosciences ( RNA ) shares were up more than 2% in recent premarket activity.

Price: 48.50, Change: +1.38, Percent Change: +2.92